Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis
Cancer Cytopathology · 2026-06 · 134 (6)
DOI: 10.1002/cncy.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 18.05.2026. Verfasst von Weijie Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, …. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Pleural Effusion, Malignant, Biomarkers, Tumor. Die Arbeit nennt 64 Literaturangaben. Gefördert von: BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
Background
Malignant serous effusions (MSEs), including pleural, pericardial, and peritoneal effusions, are common in advanced lung adenocarcinoma (LUAD). However, integrated clinicopathologic, molecular, treatment, and outcome data across effusion sites remain incompletely defined.
Methods
This study retrospectively analyzed 120 cytology‐confirmed LUAD‐associated MSE cases from a single academic center by integrating gross fluid features, cytopathology, immunohistochemistry, targeted next‐generation sequencing (NGS), systemic therapy, and clinical outcomes, including survival from first malignant effusion (SME) and overall survival (OS).
Results
Effusions were pleural (85 of 120; 70.8%), pericardial (28 of 120; 23.3%), and peritoneal (7 of 120; 5.8%). Median SME was 3.8 months, and was shortest in the small peritoneal effusion subgroup (1.0 months). OS differed by site, with pericardial involvement showing the shortest OS (6.1 months). Thyroid transcription factor 1 (TTF‐1) was positive in 72.5% of cases. Programmed death ligand 1 (PD‐L1) testing ( n = 85) showed a tumor proportion score (TPS) of ≥1% in 80% of cases and TPS of ≥50% in 36.5% of cases. Molecular profiling was completed in 111 of 120 cases (92.5%) by identifying TP53 mutations in 47 of 111 (42.3%) and actionable driver alterations in 42.3% of cases, most commonly involving EGFR , KRAS , BRAF , ALK , and ROS1 . TTF‐1 positivity was associated with higher rates of actionable driver alterations and higher PD‐L1 expression. PD‐L1 negativity, TTF‐1 negativity, and an absence of actionable driver alterations were associated with shorter SME and OS. Dual TTF‐1/PD‐L1 negativity defined the poorest risk subgroup (median SME, 1.2 months; median OS, 1.4 months). Multivariable analysis confirmed that TTF‐1 negativity and a lack of actionable drivers remained independently adverse. Among treated patients, immunotherapy‐based regimens were associated with the longest SME (6.7 months), whereas tyrosine kinase inhibitor–based therapy was associated with the longest OS (26.0 months).
Conclusions
Integration of cytology, immunophenotype, genomics, and treatment delineates distinct prognostic subsets in LUAD with MSE. The absence of actionable driver alterations and TTF‐1 negativity remains an independent adverse prognostic factor, with dual TTF‐1/PD‐L1‐negative MSE showing particularly poor SME and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, California, USA.
ORCID-Profile: Weijie Ma, Jiannan Li, Darcy A Kerr, Laura J Tafe, Xiaoying Liu
Förderung
- BLRD VA
- NCI NIH HHS
Zitieren
APA
Ma, W., Li, J., Ould Ismail, A. A., Li, T., Kerr, D. A., Tafe, L. J., & Liu, X. (2026). Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis. Cancer Cytopathology, 134(6). https://doi.org/10.1002/cncy.70108
Vancouver
Ma W, Li J, Ould Ismail AA, Li T, Kerr DA, Tafe LJ, et al. Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis. Cancer Cytopathology. 2026;134(6). doi:10.1002/cncy.70108
BibTeX
@article{Ma2026,
author = {Ma, Weijie and Li, Jiannan and Ould Ismail, A Aziz and Li, Tianhong and Kerr, Darcy A and Tafe, Laura J and Liu, Xiaoying},
title = {Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis},
journal = {Cancer Cytopathology},
year = {2026},
volume = {134},
number = {6},
doi = {10.1002/cncy.70108}
}
EUVIMED